News

Press releases

T.J. Stalvey Joins NX Development Corp. (NXDC) as Vice President of Clinical Development and Medical Affairs

LEXINGTON, KY |GlobeNewswire| April 15, 2021 — NX Development Corp. (NXDC), a life-sciences company wholly owned by photonamic GmbH & Co. KG., today announced that…

NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma

Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) — NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today…

NX DEVELOPMENT CORP. (NXDC) LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL (NXDC-MEN-301)

“We are pleased to initiate this landmark study evaluating the utility of fluorescence-guided surgery (FGS) in the meningioma patient population. We are excited about the…

Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization

Dr. Christian Ramsey first neurosurgeon in state to use GleolanTM for enhanced visualization of high-grade gliomas/glioblastoma

AANS 2019

NX Development made an appearance at AANS 2019 in San Diego, CA!

NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)

NX Development Corp. (NXDC) Launches FDA-Approved GleolanTM (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas).